Aeglea Bio Thera

$4.59 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Aeglea Bio Thera

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a human enzyme therapeutics as advanced solutions for rare and other high-burden diseases. The Company’s product candidates are Pegzilarginase, ACN00177 and AEB5100. Its Pegzilarginase is a recombinant human Arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase One Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its ACN00177 is a PEGylated or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria.

Stock Analysis

last close $4.6
1-mo return 13.6%
3-mo return -39.8%
avg daily vol. 276.99T
52-week high 8.79
52-week low 3.47
market cap. $224M
forward pe -
annual div. -
roe -57.1%
ltg forecast -
dividend yield -
annual rev. $15M
inst own. 92.6%

Subscribe now for daily local and international financial news